"Point Of Novelty" Test Remains For Design Patent Infringement
Client Alert | 1 min read | 02.23.06
In Lawman Armor Corporation v. Winner International, LLC et al. (No. 05-1253; February 22, 2006), a Federal Circuit panel affirms a district court's summary judgment of non-infringement of a design patent for a vehicle steering wheel lock assembly. In the district court , Lawman identified eight points of novelty of the patented design , to which Winner responded by identifying patents depicting each of those eight points. Accordingly, the district court found that the points of novelty were found in the prior art and granted summary judgment of non-infringement. The panel finds that Lawman made no attempt to show that the district court erred in its decision providing that the eight points of novelty are disclosed in the prior art. The Federal Circuit panel rejects Lawman's argument that there was no suggestion to combine the prior art elements to achieve the patented design, essentially arguing that the combination of the prior art elements is itself a ninth point of novelty. This decision maintains the long-standing "point of novelty" design patent infringement test, namely, that an accused device must appropriate the novel features of the patented design, specifically those features that distinguish it from the prior art.
Insights
Client Alert | 4 min read | 08.29.25
Gender-Affirming Care Targeted for Potential False Claims Act Enforcement
On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments.
Client Alert | 4 min read | 08.28.25
9th Circuit Marches Forward to the Future Finding Digital Assets Are Protected Under Trademark Law
Client Alert | 2 min read | 08.27.25
CPSC Maintains Momentum on eFiling Requirements for Consumer Products
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions